{"id":251275,"date":"2024-01-02T00:00:00","date_gmt":"2024-01-02T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epibon0001-biopharma-alk-epidemiology-mature-markets-data\/"},"modified":"2026-04-25T11:22:14","modified_gmt":"2026-04-25T11:22:14","slug":"epibon0001-biopharma-alk-epidemiology-mature-markets-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epibon0001-biopharma-alk-epidemiology-mature-markets-data\/","title":{"rendered":"ALK &#8211; Epidemiology &#8211; Mature Markets Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of anaplastic lymphoma kinase (<abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr>) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of <abbr data-abbreviation-entity=\"4727\" title=\"anaplastic lymphoma kinase\">ALK<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>The patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr data-abbreviation-entity=\"4727\" title=\"anaplastic lymphoma kinase\">ALK<\/abbr>-mutated cancer?<\/li>\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"4727\" title=\"anaplastic lymphoma kinase\">ALK<\/abbr>-mutated cancer, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"4727\" title=\"anaplastic lymphoma kinase\">ALK<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 44 <abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr>-mutated cancer populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <em><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/em>-mutated cancer by primary tumor site.<\/li>\n<li>Diagnosed incident cases of <em><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/em>-mutated cancer by metastatic status.<\/li>\n<li>Diagnosed first-line drug-treatable population of <em><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/em>-mutated cancer by site of primary tumor.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251275","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251275\/revisions"}],"predecessor-version":[{"id":281199,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251275\/revisions\/281199"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}